Page last updated: 2024-10-28

hydroxychloroquine and Dysmyelopoietic Syndromes

hydroxychloroquine has been researched along with Dysmyelopoietic Syndromes in 1 studies

Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Muslimani, AA1
Spiro, TP1
Chaudhry, AA1
Daw, HA1

Other Studies

1 other study available for hydroxychloroquine and Dysmyelopoietic Syndromes

ArticleYear
Secondary myelodysplastic syndrome after hydroxychloroquine therapy.
    Annals of hematology, 2007, Volume: 86, Issue:7

    Topics: Aged; Female; Humans; Hydroxychloroquine; Male; Myelodysplastic Syndromes; Retrospective Studies; Rh

2007